ArQule, Inc. clinical trials
Acquired by Merck & Co., Inc, Jan 16, 2020 · source ↗
The registry lists 32 studies whose lead sponsor is ArQule, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 12, 2026.
- 32studies on the registry
- 0open to participants now
- 1reach primary completion within a year
Before and after it joined Merck & Co., Inc
- First submitted before ArQule, Inc. became part of Merck & Co., Inc
- 32
- First submitted after ArQule, Inc. became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs ArQule, Inc.’s studies test, most studies first; none is open now — 4 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
Coming up
1 of ArQule, Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- 1SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 32 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 509
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 8 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)32 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 32 of 32. All Merck & Co., Inc studies →
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)TerminatedNCT02761694Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)TerminatedNCT03094832Phase 1/2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular AnomaliesNo longer availableNCT03317366
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) ProtocolsCompletedNCT01178411Phase 1/2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Open-label Phase 1b Study of ARQ 092 in Combination With AnastrozoleTerminatedNCT02476955Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT01395758Phase 2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant LymphomaCompletedNCT01473095Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue SamplesCompletedNCT02762721
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- A Study of ARQ 171 in Patients With Advanced Solid TumorsTerminatedNCT00398840Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid TumorsCompletedNCT00827177Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy RegimenWithdrawnNCT01070290Phase 2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS MutationsCompletedNCT01225536Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic TherapyCompletedNCT00988741Phase 2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- An Extension Study for Patients Previously Treated With ARQ 501CompletedNCT00622063Phase 1/2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00777309Phase 2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic AdenocarcinomaCompletedNCT00558207Phase 2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Phase 2 Study in Patients With MiT TumorsCompletedNCT00557609Phase 2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid TumorsCompletedNCT00612703Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid TumorsCompletedNCT00874042Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid TumorsCompletedNCT00612209Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)CompletedNCT00802555Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid TumorsCompletedNCT00524524Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic MalignanciesCompletedNCT00825487Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- ARQ 197 in Subjects With Metastatic Solid TumorsCompletedNCT00302172Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Safety and Efficacy Study of ARQ 501 in Adult Patients With LeiomyosarcomaCompletedNCT00310518Phase 2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic CancerCompletedNCT00102700Phase 2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and NeckCompletedNCT00358930Phase 2
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- ARQ 501 in Combination With Docetaxel in Patients With CancerCompletedNCT00099190Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- ARQ 501 in Subjects With CancerCompletedNCT00075933Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) GenotypeCompletedNCT00651638Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc
- Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy VolunteersCompletedNCT00658554Phase 1
Sponsor listed in the registry: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · First submitted before ArQule, Inc. became part of Merck & Co., Inc